| Catalog Number | I004930 |
| CAS Number | 80418-24-2 |
| Molecular Formula | C47H80O18
|
| Purity | 95% |
| Solubility | 10 mM in DMSO |
| Storage | 3 years -20℃ powder |
| IUPAC Name | (2S,3R,4S,5S,6R)-2-[(2S)-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol |
| InChI | InChI=1S/C47H80O18/c1-21(2)10-9-13-47(8,65-41-37(59)34(56)32(54)26(18-48)62-41)22-11-15-45(6)30(22)23(50)16-28-44(5)14-12-29(52)43(3,4)39(44)25(17-46(28,45)7)61-42-38(35(57)33(55)27(19-49)63-42)64-40-36(58)31(53)24(51)20-60-40/h10,22-42,48-59H,9,11-20H2,1-8H3/t22-,23+,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34-,35-,36+,37+,38+,39-,40-,41-,42+,44+,45+,46+,47-/m0/s1 |
| InChIKey | LLPWNQMSUYAGQI-OOSPGMBYSA-N |
| SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(CO6)O)O)O)C)O)C)OC7C(C(C(C(O7)CO)O)O)O)C |
| Reference | <p style=/line-height:25px/>
<br>[1]. Yang Y, et al. Notoginsenoside R1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding RNA AK094457. Int J Clin Exp Pathol. 2015 Mar 1;8(3):2700-9.
<br>[2]. Li Zhi, et al. Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer&aposs; Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation. Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer&aposs; Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation, Volume 14, Number 3, April 2015, pp. 360-369(10)
<br>[3]. PU Xian-hong, et al. The Effect of Notoginsenoside R1 on TGF-β1/smad3 Signal Pathway in Hepatic Fibrosis Rats. Progress in Modern Biomedicine,
2015-04
</p>
|
